Hyderabad, India-based contract development and manufacturing organisation (CDMO) Aragen has raised $100 million in funding from private equity group Quadria Capital that will be used to support ...

Drug Discovery Today, 26(6), pp.1409-1419. About the authors Dr Satinder Singh is working as principal scientific manager of DMPK at Aragen Life Sciences and has 18 years of diversified experience ...

Fund III is already nearly 40 per cent deployed, with investments in Aragen Life Sciences, NephroPlus, and Maxivision. Two additional transactions in Southeast Asia are expected to close soon, the ...

Quadria's Fund III, 40% deployed, backs Aragen, NephroPlus, and Maxivision, aiming to build a 10-company portfolio delivering scalable, accessible healthcare across Asia through strategic majority ...